SCHEMBL2238063

SCHEMBL2238063

O=C(On1c(=O)n(OC(=O)c2ccccc2)c(=O)n(OC(=O)c2ccccc2)c1=O)c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.54
F2 P00734 1/20 0.54
TSHR P16473 4/20 0.50
KMT2A Q03164 4/20 0.47
MAPT P10636 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
TDP1 Q9NUW8 3/20 0.45
TP53 P04637 1/20 0.45
ALDH1A1 P00352 4/20 0.44
MAPK1 P28482 1/20 0.44
HIF1A Q16665 1/20 0.44
POLB P06746 1/20 0.44
SLC6A2 P23975 1/20 0.44
SLC6A3 Q01959 1/20 0.44
HSD17B10 Q99714 1/20 0.42
CES2 O00748 2/20 0.42
CES1 P23141 2/20 0.42
DAO P14920 1/20 0.42
NAPRT Q6XQN6 1/20 0.42
GSK3A P49840 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4023905 0.88 TSHR (0.48) LMNAF2TSHRKMT2AMAPT
SCHEMBL4022180 0.82 LMNA (0.48) LMNAF2TSHRKMT2AMAPT
SCHEMBL859906 0.80 TSHR (0.48) LMNAF2TSHRKMT2AMAPT
SCHEMBL3506128 0.79 TSHR (0.52) LMNAF2TSHRKMT2AMAPT
SCHEMBL27800832 0.78 F2 (0.48) LMNAF2TSHRKMT2AMAPT
SCHEMBL1232166 0.75 LMNA (0.50) LMNAF2TSHRKMT2AMAPT
SCHEMBL5179763 0.75 CA12 (0.43) LMNAF2TSHRKMT2AMAPT
Fluoride SCHEMBL726494 0.75 LMNA (0.61) LMNAF2TSHRKMT2AMAPT
SCHEMBL3494816 0.74 LMNA (0.54) LMNAF2TSHRKMT2AMAPT
SCHEMBL11260959 0.74 LMNA (0.48) LMNAF2TSHRKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7994330-B2 Oxidizing p-xylene to terephthalic acid using a catalyst having a dicarboximide skeleton; hydrothermally treating the product with hot water, decomposing and removing catalyst impurities DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2011-08-09 US disclosed
US-7524986-B2 Methods for producing aromatic carboxylic acids DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2009-04-28 US disclosed
US-20080171881-A1 Method for Producing Organic Compound and Method for Decomposing Compound Having Dicarboximide Skeleton DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2008-07-17 US disclosed
EP-1870394-A1 METHOD FOR PRODUCING ORGANIC COMPOUND AND METHOD FOR DECOMPOSING COMPOUND HAVING DICARBOXYIMIDE SKELETON Daicel Chemical Industries, Ltd. (JP) 2007-12-26 EP disclosed
US-20070191634-A1 Methods for producing aromatic carboxylic acids DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2007-08-16 US disclosed
EP-1734029-A1 PROCESS FOR PRODUCING AROMATIC CARBOXYLIC ACID Daicel Chemical Industries, Ltd. (JP) 2006-12-20 EP disclosed
US-7091342-B2 Catalyst comprising cyclic acylurea compounds and processes for production organic compounds with the same DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2006-08-15 US disclosed
US-7034184-B2 Process for producing azine compounds and oxime compounds DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2006-04-25 US disclosed
US-20050020439-A1 Catalyst comprising cyclic acylurea compounds and processes for production organic compounds with the same DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2005-01-27 US disclosed
US-6768023-B2 REACTING AN ESTER OR SALT OF NITROUS ACID WITH A COMPOUND THAT GENERATES A FREE RADICAL IN THE PRESENCE OF A NITROGEN CONTAINING CYCLIC COMPOUND CONTAINING AN N-OXY OR -HYDROXY IMIDE GROUP; FORMING OXIMES, NITRO COMPOUNDS, AND KETONES DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2004-07-27 US disclosed
US-20030204084-A1 Process for producing azine compounds and oxime compounds DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2003-10-30 US disclosed
US-20030171618-A1 Process for producing organic compounds using nitrites DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2003-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030204084-A1 Process for producing azine compounds and oxime compounds CBR1, DAO, ALKBH2 LMNA 3050/4885F2 1262/4885TSHR 198/4885
US-20030171618-A1 Process for producing organic compounds using nitrites NOS1, NOS2, NOS3 LMNA 2540/4885F2 1189/4885TSHR 2997/4885
US-20080171881-A1 Method for Producing Organic Compound and Method for Decomposing Compound Having Dicarboximide Skeleton DHPS, OGDH, MCCC2 LMNA 1905/4885F2 481/4885TSHR 4661/4885
US-20070191634-A1 Methods for producing aromatic carboxylic acids PAH, AHR, HAO2 LMNA 3635/4885F2 515/4885TSHR 2348/4885
US-20050020439-A1 Catalyst comprising cyclic acylurea compounds and processes for production organic compounds with the same MOGAT2, ACSS2, ACOX1 LMNA 4215/4885F2 2558/4885TSHR 1846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.